Risk factors
Cue Biopharma (CUE) risk factors
Item 1A of every Cue Biopharma, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors74 risks16 new10 dropped19 reworded
Cue Biopharma prioritized autoimmune programs, licensing CUE-501 to BI and CUE-100 series to IMSCP.
Filed Mar 16, 2026 - FY2024 10-K risk factors68 risks
Cue Biopharma faces severe going concern doubts with $22.5 million in cash and an accumulated deficit of $340.9 million as of December 31, 2024. The company prioritizes preclinical autoimmune programs like CUE-401 and CUE-501 while seeking external partners for the CUE-100 and CUE-500 series.
Filed Mar 31, 2025